MOESM10 of Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer

Additional file 10: Overall survival analysis of metastatic breast cancer patients, showing the p-value, Hazard ratio and the 95% confidence interval for this Hazard ratio. Comparison of joint analysis of new blood biomarkers (CTCs and cfDNA) against traditional biomarkers (CA15-3 and AP). Stratified biomarkers as variables. Overall survival population results from joint analysis of biomarkers.

附加文件10：转移性乳腺癌患者总生存期分析，展示了该分析的p值、风险比（Hazard Ratio, HR）及其95%置信区间。本研究对比了新型血液生物标志物（CTCs与cfDNA）联合分析与传统生物标志物（CA15-3与AP）联合分析的结果，以分层处理后的生物标志物作为研究变量，涵盖生物标志物联合分析得到的总生存期人群研究结果。